Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
HCW Biologics Inc (HCWB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/11/2025: HCWB (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $35
1 Year Target Price $35
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 33.03% | Avg. Invested days 44 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 07/11/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 11.04M USD | Price to earnings Ratio - | 1Y Target Price 35 |
Price to earnings Ratio - | 1Y Target Price 35 | ||
Volume (30-day avg) 1 | Beta 0.83 | 52 Weeks Range 3.55 - 62.40 | Updated Date 07/12/2025 |
52 Weeks Range 3.55 - 62.40 | Updated Date 07/12/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -24.8 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -78298.16% |
Management Effectiveness
Return on Assets (TTM) -57.2% | Return on Equity (TTM) -27725.96% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 23873772 | Price to Sales(TTM) 7.64 |
Enterprise Value 23873772 | Price to Sales(TTM) 7.64 | ||
Enterprise Value to Revenue 16.52 | Enterprise Value to EBITDA -3.63 | Shares Outstanding 2538320 | Shares Floating 731958 |
Shares Outstanding 2538320 | Shares Floating 731958 | ||
Percent Insiders 29.8 | Percent Institutions 1.47 |
Upturn AI SWOT
HCW Biologics Inc
Company Overview
History and Background
HCW Biologics Inc. is a biopharmaceutical company focused on discovering and developing innovative immunotherapies to address unmet needs in cancer, age-related diseases, and autoimmune conditions. Founded in 2018, the company's core technology is based on its TOBIu2122 (Tissue microenvironment-resident Onco-immunotherapies) platform.
Core Business Areas
- Drug Discovery & Development: HCW Biologics focuses on discovering and developing novel biologic therapeutics using its TOBIu2122 platform. This includes identifying therapeutic targets, designing drug candidates, and conducting preclinical and clinical studies.
- TOBIu2122 Platform Technology: The company's proprietary TOBIu2122 platform is at the core of its drug development efforts. This platform allows for the development of novel biologics that target specific disease microenvironments.
- Clinical Trials: HCW Biologics conducts clinical trials to evaluate the safety and efficacy of its drug candidates in human patients. These trials are essential for obtaining regulatory approval and bringing new therapies to market.
Leadership and Structure
Hing C. Wong is the Founder and CEO. The company has a research and development team focusing on drug discovery and clinical development.
Top Products and Market Share
Key Offerings
- HCW9218: Lead drug candidate, a TOBIu2122 molecule designed to target age-related diseases and certain cancers. Currently in Phase 1 clinical trials. Market share is currently 0, as it's still in clinical trials. Competitors include companies developing therapies for similar indications (e.g., anti-aging and cancer immunotherapies).
- HCW7202: Another TOBIu2122 molecule targeting cancer. Preclinical development is ongoing. Market share is currently 0. Competitors are cancer therapeutics developers.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and dynamic, with significant investments in research and development. The immunotherapy market, in particular, is experiencing rapid growth due to the increasing prevalence of cancer and autoimmune diseases.
Positioning
HCW Biologics is positioned as an innovative immunotherapy company leveraging its TOBIu2122 platform. Its competitive advantage lies in its novel approach to targeting disease microenvironments.
Total Addressable Market (TAM)
The total addressable market for immunotherapies is substantial and growing. The immunotherapy market is projected to reach hundreds of billions of dollars in the coming years. HCW Biologics aims to capture a portion of this market with its pipeline of TOBIu2122-based therapeutics.
Upturn SWOT Analysis
Strengths
- Proprietary TOBIu2122 platform technology
- Innovative approach to immunotherapy
- Strong scientific leadership
- Targeting unmet medical needs
Weaknesses
- Early-stage development pipeline
- Reliance on funding for clinical trials
- Small company size compared to established competitors
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Growing demand for immunotherapies
Threats
- Clinical trial failures
- Competition from established immunotherapy companies
- Regulatory hurdles
- Patent challenges
Competitors and Market Share
Key Competitors
- MRNA
- PFE
- BMY
Competitive Landscape
HCW Biologics faces competition from large pharmaceutical companies with established immunotherapy platforms. HCW's advantage lies in its TOBIu2122 technology's potential to provide more targeted and effective therapies.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by preclinical and early-stage clinical development.
Future Projections: Future growth is dependent on successful clinical trials, regulatory approvals, and commercialization of its therapies.
Recent Initiatives: Focusing on advancing HCW9218 through Phase 1 clinical trials and expanding the TOBI platform.
Summary
HCW Biologics is an early-stage biopharmaceutical company with a novel immunotherapy platform. The company's success hinges on positive clinical trial results for its lead drug candidates. The company faces stiff competition in the immunotherapy market but has the potential to disrupt the field with its innovative TOBIu2122 technology. Securing partnerships and additional funding will be important.
Peer Comparison
Sources and Disclaimers
Data Sources:
- HCW Biologics Inc. Website
- Sec Filings
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market share data is estimated and may not be precise. Investment decisions should be based on thorough due diligence and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About HCW Biologics Inc
Exchange NASDAQ | Headquaters Miramar, FL, United States | ||
IPO Launch date 2021-07-20 | Founder, CEO, Director & Secretary Dr. Hing C. Wong Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 36 | Website https://www.hcwbiologics.com |
Full time employees 36 | Website https://www.hcwbiologics.com | ||
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, a clinical-stage bifunctional molecule, which has completed Phase 1 to treat chemotherapy-refractory solid tumor cancers and Phase 1b/2 to treat pancreatic cancer; and HCW9302, injectable and interleukin 2 (IL-2) fusion protein complex, which is in phase 1 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201 and HCW9206, novel immunotherapeutic for memory-like natural killer cells, cancer, and pathogens; HCW11-006, an immune cell stimulator; HCW11-002 and HCW11-0027, which are immune checkpoint inhibitors to treat oncology and other senescence-associated indications; and HCW11-018, a fusions and immune cell engagers to treat cancer. The company has a license agreement with Wugen Inc. to develop cell therapy-based treatments; and a license, research and co-development agreement with WY Biotech Co., Ltd. for its preclinical molecules. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.